These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24128775)

  • 21. An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working Group.
    Finger ME; Boonen A; Woodworth TG; Escorpizo R; Christensen R; Nielsen SM; Leong AL; Scholte Voshaar M; Flurey CA; Milman N; Verstappen SM; Alten R; Guillemin F; Kloppenburg M; Beaton DE; Tugwell PS; March LM; Furst DE; Pohl C
    J Rheumatol; 2017 Nov; 44(11):1734-1739. PubMed ID: 28461648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018.
    Chiarotto A; Kaiser U; Choy E; Christensen R; Conaghan PG; Cowern M; Gill M; de Wit M; Gargon E; Horgan B; Kirkham JJ; Simon LS; Singh JA; Tugwell P; Turk DC; Mease PJ
    J Rheumatol; 2019 Oct; 46(10):1355-1359. PubMed ID: 30936284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influencing health equity: role of the effective consumer scale in measuring skills and abilities in a middle income country.
    Rader T; Ueffing E; Garcia-Elorrio E; Idzerda L; Ciapponi A; Irazola V; Welch V; Lyddiatt A; Shea B; Newman S; Osborne R; Tugwell PS
    J Rheumatol; 2011 Aug; 38(8):1798-802. PubMed ID: 21807803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials.
    Klokker L; Berthelsen DB; Woodworth T; Andersen KM; Furst DE; Devoe D; Williamson PR; Suarez-Almazor ME; Strand V; Leong AL; Goel N; Boers M; Brooks PM; March L; Sloan VS; Tugwell P; Simon LS; Christensen R
    J Rheumatol; 2019 Sep; 46(9):1173-1178. PubMed ID: 31043547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What has been the effect on trial outcome assessments of a decade of patient participation in OMERACT?
    de Wit MP; Abma TA; Koelewijn-van Loon MS; Collins S; Kirwan J
    J Rheumatol; 2014 Jan; 41(1):177-84. PubMed ID: 24128777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measures of quality, costs and equity in primary health care instruments developed to analyse and compare primary care in 35 countries.
    Schäfer WL; Boerma WG; Kringos DS; De Ryck E; Greß S; Heinemann S; Murante AM; Rotar-Pavlic D; Schellevis FG; Seghieri C; Van den Berg MJ; Westert GP; Willems S; Groenewegen PP
    Qual Prim Care; 2013; 21(2):67-79. PubMed ID: 23735688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health literacy: what is it and why is it important to measure?
    Buchbinder R; Batterham R; Ciciriello S; Newman S; Horgan B; Ueffing E; Rader T; Tugwell PS; Osborne RH
    J Rheumatol; 2011 Aug; 38(8):1791-7. PubMed ID: 21807802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0.
    Boers M; Kirwan JR; Wells G; Beaton D; Gossec L; d'Agostino MA; Conaghan PG; Bingham CO; Brooks P; Landewé R; March L; Simon LS; Singh JA; Strand V; Tugwell P
    J Clin Epidemiol; 2014 Jul; 67(7):745-53. PubMed ID: 24582946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group.
    Coates LC; Mumtaz A; Helliwell PS; Mease PJ; Callis-Duffin K; Krueger GG; McHugh NJ; Strand V; Gladman DD; FitzGerald O
    J Rheumatol; 2011 Jul; 38(7):1496-501. PubMed ID: 21724722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis: preliminary findings in the generic health OMERACT study. OMERACT/ILAR Task Force on Generic Quality of Life. Life Outcome Measures in Rheumatology. International League of Associations for Rheumatology.
    Wells G; Boers M; Shea B; Tugwell P; Westhovens R; Saurez-Almazor M; Buchbinder R
    J Rheumatol; 1999 Jan; 26(1):217-21. PubMed ID: 9918267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.
    Woodworth T; Furst DE; Alten R; Bingham CO; Yocum D; Sloan V; Tsuji W; Stevens R; Fries J; Witter J; Johnson K; Lassere M; Brooks P
    J Rheumatol; 2007 Jun; 34(6):1401-14. PubMed ID: 17552067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient perspective on outcomes in rheumatology -- a position paper for OMERACT 9.
    Kirwan JR; Newman S; Tugwell PS; Wells GA
    J Rheumatol; 2009 Sep; 36(9):2067-70. PubMed ID: 19738215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing single joints in arthritis clinical trials.
    Keen HI; Bingham CO; Bradley LA; Conaghan PG; Heald AE; Kaeley GS; Maksymowych WP; Moskowitz RW; Schumacher HR; Woodworth TE; Mease PJ
    J Rheumatol; 2009 Sep; 36(9):2092-6. PubMed ID: 19738219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The OMERACT Initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology.
    Boonen A; Maetzel A; Drummond M; Suarez-Almazor M; Harrison M; Welch V; Tugwell PS
    J Rheumatol; 2009 Sep; 36(9):2045-9. PubMed ID: 19738211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rheumatological medicine literacy among Middle Eastern populations.
    Eleishi HH; Allison BD
    Int J Rheum Dis; 2009 Dec; 12(4):336-42. PubMed ID: 20374372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of the patient perspective at OMERACT 10--conceptualizing methods for developing patient-reported outcomes.
    Kirwan JR; Tugwell PS
    J Rheumatol; 2011 Aug; 38(8):1699-701. PubMed ID: 21807788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. OMERACT 10--International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials.
    Brooks P; Boers M; Simon LS; Strand V; Tugwell P; Idzerda L
    J Rheumatol; 2011 Jul; 38(7):1450-51. PubMed ID: 21724714
    [No Abstract]   [Full Text] [Related]  

  • 38. Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014.
    Hatemi G; Ozguler Y; Direskeneli H; Mahr A; Gul A; Levi V; Aydin SZ; Mumcu G; Sertel-Berk O; Stevens RM; Yazici H; Merkel PA
    J Rheumatol; 2015 Dec; 42(12):2436-41. PubMed ID: 26373563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation studies of rheumatoid arthritis patient-reported outcome measures in populations at risk for inequity: A systematic review and analysis using the OMERACT summary of measurement properties equity table.
    Barnabe C; Wattiaux A; Petkovic J; Beaton D; Shea B; Greer-Smith R; Humphreys J; Bartels C; Tugwell P; Umaefulam V
    Semin Arthritis Rheum; 2022 Aug; 55():152029. PubMed ID: 35640489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative.
    Nielsen SM; Tugwell P; de Wit MPT; Boers M; Beaton DE; Woodworth TG; Escorpizo R; Shea B; Toupin-April K; Guillemin F; Strand V; Singh JA; Kloppenburg M; Furst DE; Wells GA; Smolen JS; Veselý R; Boonen A; Storgaard H; Voshaar M; March L; Christensen R;
    J Rheumatol; 2019 Sep; 46(9):1159-1163. PubMed ID: 30647174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.